(redirected from Myeloproliferative disorders)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
References in periodicals archive ?
Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V619F mutation in chronic myeloproliferative disorders.
Since patient had past history of myeloproliferative disorder and US scan revealed an enlarged liver we organised a CT scan abdomen and pelvis liver protocol.
Ruzzon E, Randi ML, Tezza F, Luzzatto G, Scandellari R, Fabris E Leg ulcers in elderly on hydroxyurea: a single center experience in Ph- myeloproliferative disorders and review of literature.
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.
In patients with primary nonfamilial thrombocytosis, which is a myeloproliferative disorder, the frequency of thrombosis and/or hemorrhage widely varies among various reports (20-84% for thrombotic complications and 4-41% for bleeding complications).
Patients with myeloproliferative disorders may benefit from aspirin and hydroxyurea during the course of the disease.
ORLANDO -- Thrombosis was significantly more prevalent in women, compared with men, in a review of data from 270 adults with JAK2 V617-F-positive myeloproliferative disorder, according to a poster at the meeting.
Chronic myeloproliferative disorders (CMPDs) are clonal haematopoietic stem cell disorders and include the BCR-ABL negative CMPDs like polycythemia vera (PV), essential thrombocythemia (ET), idiopathic myelofibrosis (IMF) and chronic eosinophilic leukaemia (CEL) (1,2).
Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in 2009.
Bristol-Myers Squibb has notified health care professionals about revisions to the Warnings and Adverse Reactions sections of the prescribing information to include information about vasculitic ulcerations and gangrene that have occurred in patients with myeloproliferative disorders during therapy with hydroxyurea.
Coverage includes techniques for the detection of BCR-ABL mutations and resistance to imatinib mesylate, detection of the FIP 1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia, classification of acute myeloid leukemia by DNA- oligonucleotide microarrays, detection of the V617F JAK2 mutation in myeloproliferative disorders, gene rearrangements, FLT3 mutations andWT-1 overexpression.